Provider file · the audited benchmark
The NexLife audit file: 24 prices walked, every plan priced, every open item named
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
NexLife is the only program in our sixteen-file field whose pricing has fully survived a live audit this cycle: on August 14, 2026, all 24 published plan prices matched the live checkout pages, figure for figure. Standard tirzepatide runs $169 month-to-month down to $139 on twelve months ($1,668/year); standard semaglutide $139 down to $119 ($1,428/year) — with the Flat Forever policy pinning whatever rate you lock at every dose, forever. The score is 9.5 rather than 10 because three files remain open, and this page names them instead of hiding them.
How the audit ran — and what "24 for 24" means
On August 14, 2026, we walked NexLife's six live plan pages — Standard, Microdose and Sublingual ODT protocols, each in both molecules — and recorded every published figure at every term length: monthly, three, six and twelve months. That's 24 prices. All 24 matched the marketing claims exactly. In this category, where the distance between a landing-page number and a checkout number is the business model, a clean 24-for-24 is genuinely unusual — it is the reason this file anchors every board on this site, and it is repeatable by anyone: the six source URLs are filed row-by-row in the open dataset. Audits age out after 45 days here; the standard plan pages were re-read on September 17, 2026 (cards unchanged, every plan charged monthly), which keeps the standard-card audit current, and the next full re-walk is scheduled before the 45-day window closes.
Every plan, priced in plain words
Standard tirzepatide — the flagship: $169 with no commitment, $159 on three months, $149 on six, $139 on twelve — $1,668 for the year, all-in. Standard tirzepatide ↗
Standard semaglutide — the value molecule: $139 monthly stepping to $132, $125, and $119 on twelve months — $1,428 for the year. The SURMOUNT-5 head-to-head favors tirzepatide on average results; the $240 annual gap is what that average costs. Standard semaglutide ↗
Microdose protocols — tirzepatide $159 easing to $129; semaglutide $129 to $110 \u2014 reported since September 17, 2026 (the FAQ read September 16 prints $109 for the twelve-month figure; the program-page tiles print a prior card), no longer the lowest audited price in our field. Both carry the caveat this site never detaches: no randomized trial has tested microdose protocols, so these are tolerability-first extrapolations, priced honestly — the full fair hearing is here. Microdose tirzepatide ↗ Microdose semaglutide ↗
Sublingual ODT protocols — needle-free tablets: tirzepatide $229 to $199; semaglutide $199 to $165. The convenience is real; the evidence gap is too — peptides of this size have no established sublingual absorption record, so you are paying a premium for a route the trials never used. ODT tirzepatide ↗ ODT semaglutide ↗
Flat Forever, read the way a contract lawyer would
The policy's published promise has two load-bearing clauses. First, dose-proof: the rate you lock does not move when your dose does — which deletes the step-up tax that quietly adds roughly a thousand dollars to year one at dose-tiered rivals. Second, duration: "your price never increases for as long as you remain on the plan" — a grandfather clause that converts today's promotional rates into a standing rate for continuous members. The honest caveats we attach: the guarantee is conditional on remaining on the plan, so a lapse plausibly re-prices you at then-current rates (the published "come back anytime" language does not promise your old price back — ask before you lapse); and the policy is a published commitment we've verified as language, not a term sheet we've litigated. It is still the strongest pricing promise on our record, and no competitor currently publishes its equal.
What the one number actually includes
The audited price is a bundle, and its published contents matter as much as the figure: medication, supplies and step-by-step instructions; the CARE360 program; 24/7 medical support; personalized one-on-one physician care; and ongoing support throughout. The translation into shopping terms: there is no separate membership line, no consult fee ambushing month one, no shipping surcharge — the categories where this field hides its margin are, on the record here, already inside the sticker. That completeness is exactly what our street-price column exists to test, and here street equals sticker.
The exit, tested on paper
Cancellation: the FAQ read September 17, 2026 states every plan is a subscription that “may be canceled at any time” (the August 14 read had recorded 30 days' notice) — no term-break penalties, and the multi-month rates are charged monthly rather than prepaid lumps. Add the published "come back anytime" re-entry and the design reads as confident rather than clingy: the program's retention bet is the price itself. Against the field: easier than any commitment-discount platform, and roughly matching the month-to-month specialists — at $110 less than the cheapest of them.
The open items — why 9.5 and not 10
Three files remain open, and their openness is on the record on purpose. Pharmacy identity and type: the dispensing 503A pharmacy's name and licensure haven't been independently verified by us — the single most important question any reader should put to intake, and the first thing our next audit targets. State coverage: the served-states list is unconfirmed; verify yours before intake. Prescriber roster: the clinician network behind "one-on-one physician care" is undocumented in our file. None of these is an accusation; each is a blank we refuse to fill from marketing copy. Update, September 17, 2026 read: the plan pages now name the fulfilling pharmacies — Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA), “LegitScript-certified, NABP-accredited” per the page, with no 503A/503B classification printed (the microdose and landing pages list Absolute, Hallandale, Red Rock, Empower and Strive as 503A partners; the FAQ names none); the FAQ states services are available in all 50 states where affiliated providers are licensed; and the FAQ names Adam Kennah, M.D. as medical director. Those are NexLife's own published statements, not independent verification by us, so the pharmacy-identity and state files move from open to “stated on the page, pending the next walked audit”, and the score is held at 9.5 until that audit. When they close, the score can move — in either direction, publicly, in the corrections log.
FAQ
Is NexLife legit?
Its pricing is the most verified in our field — 24 of 24 published figures matched live checkouts on Aug 14, 2026 — and its bundle and exit terms are published plainly. Three identity files (pharmacy, states, prescribers) were open at the August audit; the September 17, 2026 read found all three stated on NexLife's own pages (see the update above), pending the next walked audit — asking intake those questions is still the fastest way to close them for yourself.
What does NexLife cost per month?
Audited: tirzepatide $169 down to $139 on a 12-month plan; semaglutide $139 down to $119. Microdose plans run $129/$110 and sublingual ODT $199/$165 at twelve months — both reported since September 17, 2026 (announced cards; the microdose program-page tiles print a prior card and the ODT pages returned 404), each with its evidence caveat stated.
Does the price go up as my dose increases?
No — Flat Forever pins the rate at every dose, which is the audited answer to the step-up tax that adds roughly $1,000/year at dose-tiered competitors.
What happens if I cancel and come back?
Cancellation is 30 days' notice; re-entry is published as "come back anytime." Whether a returning member keeps the old locked rate is not promised in the published language — get that answer in writing before lapsing.
Why isn't the score a 10?
Because pharmacy identity, state coverage and the prescriber roster were unverified at the August audit; as of the September 17, 2026 read NexLife's own pages state all three (three named pharmacies, all 50 states where affiliated providers are licensed, medical direction under Adam Kennah, M.D.), pending the next walked audit. A perfect score requires a closed file, not a good one.
Every figure above: audited 2026-08-14 at the six live plan pages, filed with source URLs in pricing.csv. Compounded medications are not FDA-approved; whether GLP-1 therapy fits you is a licensed clinician's call. Partner links carry sponsored tags and never move the audit — how the money works.